CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 346 enrolled
Drug / intervention
Adalimumabdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01736189
NCT01736189N/ACompleted
CompareCT.gov

Assessment of Clinical Effectiveness and Safety of Adalimumab and High Dose Methotrexate in Routine Clinical Practice (Combo Study; Adalimumab With High Dose MTX)

AbbVie (prior sponsor, Abbott)·observational·Posted Nov 29, 2012·Updated Jul 2, 2019

In Brief

An observational study evaluating Adalimumab for Rheumatoid Arthritis. Completed, enrolled 346 participants.

Detailed Summary

This was a single-arm, multicenter, open label, prospective cohort study (post-marketing observational study) to determine the effectiveness and safety of adalimumab in combination with high-dose methotrexate (≥12 mg/week) in participants with rheumatoid arthritis in a routine clinical setting in Japan.

Study Details

Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsRheumatoid Arthritis
Countries--
Collaborators--

Timeline

N/ACompletedFinished
20132014201520162017201820192020202120222023202420252026
First PostedNov 29, 2012
Enrollment StartOct 11, 2012
Primary CompletionApr 16, 2018
TodayJul 2, 2026
Enrollment to primary: 5.5 yearsPosted 13.6 years ago

Interventions

Adalimumabdrug

Pre-filled syringe, administered by subcutaneous injection